WuXi Biologics (Cayman) Inc. (2269.HK)

HKSE · Healthcare · Biotechnology
40.96 HKD-6.57%As of 2026-11-22 · HKD
Last session low 40.30 HKDLast session high 42.70 HKD
52-week low 28.48 HKD52-week high 58.00 HKD
Market cap (USD)
$21.51B
Sector
Healthcare
P/E (TTM)
30.8x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in HKD.

IndicatorValueReading
RSI (14)31.1In the neutral range (30 to 70)
MACD (12, 26, 9)-1.33Below its signal line (-0.88); histogram -0.45
Bollinger %B (20, 2)-8%Below the lower band (41.71 to 50.71)
SMA 2046.21Price is 11.4% below
SMA 5049.35Price is 17.0% below
SMA 20040.53Price is 1.1% above
ATR (20)6.47% of priceAverage true range per day
52-week position42%In the middle of the 28.48 to 58.00 range

About WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC.

Insider filings, 90 daysNo purchases and 1 sale (about 20.2M HKD).
Latest fiscal yearEnded 2025-12-31: revenue of 21.79B CNY and an operating margin of 32.4%.

More in Biotechnology